Saturday 17 October 2026
Export NNNN’s income statement to Excel — free account
Anbio Biotechnology
NNNN Healthcare Medical Instruments & Supplies
Anbio Biotechnology’s revenue for fiscal 2025 (year ended December 2025) was $8.6 million, up 5.64% from fiscal 2024.
3.29
0.01
−0.30%
Follow NNNN
| Dec '25 | Jun '25 | Dec '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
344.45 | 211.14 | 10.71 | 15.86 |
+1 more quarter Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | — | — | — | |
Operating CF/Net income |
0.00 | — | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | — | 0.00 | 0.00 | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | — | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(6.74) | — | 2.08 | 0.90 | |
Working Capital |
30.16 | 27.55 | 16.80 | 14.76 | |
Capital Expenditures |
0.00 | — | 0.00 | 0.00 | |
Net Current Asset Value |
30.16 | 27.55 | 16.80 | 14.76 | |
| Other line items | |||||
Quick Ratio |
177.19 | 130.78 | 7.41 | 11.65 | |
Operating CF per Share |
0.00 | — | 0.00 | 0.00 | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Average Assets |
22.10 | — | — | — | |
Average Common Equity |
21.35 | — | — | — | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates